CTAD 2022

Nov 29-Dec 2, San Francisco, CA.

Every year, the Clinical Trials on Alzheimer’s Disease conference (CTAD) brings together leaders in academia and industry to share and debate the latest in Alzheimer’s disease therapeutic trials. CTAD 2022 featured highly anticipated late-phase research news, as well as introductions to novel agents, ongoing studies, and cutting-edge clinical trial strategies.

Explore our coverage below!

View all videos

Popular new uploads

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Alvaro Pascual-Leone • 9 Jan 2023

Identifying dementia with Lewy bodies in the presence of Alzheimer’s disease

Carla Abdelnour • 29 Nov 2022

The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia

Hussein Yassine • 30 Nov 2022

Long-term transdermal nicotine for the treatment of mild cognitive impairment

Paul Newhouse • 23 Nov 2022

Lecanemab news

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

Nicolas Villain • 6 Dec 2022

Lecanemab: a review

Alvaro Pascual-Leone • 9 Jan 2023

Novel treatments

New pivotal study using photobiomodulation in Alzheimer’s treatment

Jacques Touchon • 9 Dec 2022

Nilotinib: a potential repurposed treatment for Alzheimer’s disease?

Charbel Moussa • 28 Nov 2022

Improving diagnosis & prognostication

Speech biomarker for cognition: a novel marker for AD clinical trial screening

Nicklas Linz • 8 Dec 2022

The diagnostic and prognostic performance of U-p53AZ as a blood-based biomarker for AD

Paul Kinnon • 21 Nov 2022

Biomarkers for early detection of Alzheimer’s disease: microRNAs

Bruno Steinkraus • 1 Dec 2022

Associations between predicted brain age and Alzheimer’s Disease biomarkers

Irene Cumplido-Mayoral • 25 Nov 2022